ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

anti-TL1A monoclonal antibody, low dose

Also written as “anti-TL1A monoclonal antibody, medium dose” and “anti-TL1A monoclonal antibody, high dose”.

Its studies are mostly in Colitis, Ulcerative · Crohn Disease, led by Biocad.

Furthest: phase 2, since Jul 14, 20252 company-led studies, 2 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biocad22 open or runningphase 2since Jul 14, 2025Jul 14, 2025Jan 2027phase 2 · NCT07080034

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2025First studies: 2 phase 2 studiesFirst studyNCT07078994, NCT07080034

Ahead

  1. Jan 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT07080034
  2. May 2027Primary completion: phase 2 study in Crohn DiseaseNCT07078994

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07080034Colitis, Ulcerative · Russia2RecruitingJan 2027198
NCT07078994Crohn Disease · Russia2RecruitingMay 2027204

How it is read

Names in the registry

  • “anti-TL1A monoclonal antibody, low dose”, 2 entries
  • “anti-TL1A monoclonal antibody, medium dose”, 2 entries
  • “anti-TL1A monoclonal antibody, high dose”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.